On 31 March 2008, H. Lundbeck A/S was notified that LFI A/S (the
Lundbeck Foundation) has reduced its holding of Lundbeck shares to
138,130,340 shares in connection with Lundbeck's share buyback
programme. LFI subsequently holds 66,64% of the shares in Lundbeck.
LFI will once again hold approximately 70% of Lundbeck's shares in
connection with the scheduled redemption of Lundbeck's treasury
shares after the annual general meeting on 22 April 2008.
The content of this release will have no influence on the Lundbeck
Group's financial result for 2008.
Lundbeck contacts
Investorer: Presse:
Jacob Tolstrup Anders Schroll
Director Head of Communication
+45 36 43 30 79 +45 36 43 20 81
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26
Stock Exchange Release No 331 - 31 March 2008
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2007,
the company's revenue was DKK 11 billion (approximately EUR 1.5
billion or USD 2.0 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
